Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31217589 | 0.85 | KDM4E (0.53) | CA2KDM4EMAPTALDH1A1GLA | |
| SCHEMBL18407415 | 0.85 | KDM4E (0.53) | CA2KDM4EMAPTALDH1A1GLA | |
| SCHEMBL24958682 | 0.84 | CA2 (0.51) | CA2NR1I3ABCB1PLK1THRA | |
| SCHEMBL17974165 | 0.82 | CA2 (0.53) | CA2NR1I3PLK1THRATHRB | |
| SCHEMBL15241836 | 0.82 | CA2 (0.53) | CA2NR1I3PLK1THRATHRB | |
| SCHEMBL24770627 | 0.82 | CA2 (0.57) | CA2NR1I3PLK1THRATHRB | |
| SCHEMBL4743772 | 0.82 | CA2 (0.53) | CA2NR1I3PLK1THRATHRB | |
| SCHEMBL5860509 | 0.79 | EYA3 (0.49) | ABCB1PLK1THRBCYP2C19EYA3 | |
| SCHEMBL1253476 | 0.79 | CA2 (0.62) | CA2NR1I3ABCB1PLK1THRA | |
| SCHEMBL20562108 | 0.79 | CA2 (0.54) | CA2NR1I3PLK1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20230011568-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-01-12 | — | — | US | disclosed |
| WO-2022268890-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2022-12-29 | — | — | WO | disclosed |
| CN-113825409-A | Whiskey imitation made from individual components | 艾娃食品实验室有限公司 | 2021-12-21 | — | — | CN | disclosed |
| US-20210380618-A1 | ORGANIC LIGHT EMITTING MATERIAL | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20190169195-A1 | BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-06-06 | — | — | US | disclosed |
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2687533-A2 | Acrylamide derivatives as FAB I inhibitors | Affinium Pharmaceuticals, Inc. (CA) | 2014-01-22 | — | — | EP | disclosed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-09-12 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| WO-2008084236-A1 | CHEMICAL COMPOUNDS 635 : PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | MCL1, DHFR, ANXA5 | CA2 1146/4885NR1I3 4651/4885ABCB1 446/4885 |
| US-20230011568-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | L1CAM, AP1M1, AP2M1 | CA2 3423/4885NR1I3 1349/4885ABCB1 4129/4885 |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | CA2 1811/4885NR1I3 2336/4885ABCB1 2329/4885 |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | CA2 3128/4885NR1I3 645/4885ABCB1 74/4885 |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | CA2 3128/4885NR1I3 645/4885ABCB1 74/4885 |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | CA2 4674/4885NR1I3 2836/4885ABCB1 166/4885 |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | MCL1, DHFR, ANXA5 | CA2 1146/4885NR1I3 4651/4885ABCB1 446/4885 |
| US-20210380618-A1 | ORGANIC LIGHT EMITTING MATERIAL | LEF1, CRY1, CYBA | CA2 3813/4885NR1I3 474/4885ABCB1 2081/4885 |
| US-20190169195-A1 | BET PROTEIN DEGRADERS | BRD4, BET1, BRD1 | CA2 3421/4885NR1I3 1247/4885ABCB1 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.